Compare · GHM vs TMO
GHM vs TMO
Side-by-side comparison of Graham Corporation (GHM) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GHM and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.52B, about 156.8x GHM ($1.11B).
- Over the past year, GHM is up 108.6% and TMO is up 14.9% - GHM leads by 93.7 points.
- GHM has been more active in the news (23 items in the past 4 weeks vs 17 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 9 for GHM).
- Company
- Graham Corporation
- Thermo Fisher Scientific Inc
- Price
- $93.11-12.90%
- $469.56-0.67%
- Market cap
- $1.11B
- $174.52B
- 1M return
- -4.41%
- -1.03%
- 1Y return
- +108.59%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 1978
- News (4w)
- 23
- 17
- Recent ratings
- 9
- 25
Graham Corporation
Graham Corporation, together with its subsidiaries, designs, manufactures, and supplies vacuum and heat transfer equipment for the chemical, defense, petrochemical, petroleum refining, power generation/alternative energy, and other industries. It offers heat transfer equipment, including surface condensers, heliflows, water heaters, and various types of heat exchangers, as well as custom-engineered ejectors; vacuum equipment, such as steam jet ejector vacuum systems and liquid ring vacuum pumps; and turbomachinery products for the aerospace, cryogenic, defense, and energy markets. The company also services and sells spare parts for its equipment. It sells its products directly, as well as through independent sales representatives in the United States, the Middle East, Canada, Asia, South America, and internationally. Graham Corporation was founded in 1936 and is headquartered in Batavia, New York.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest GHM
- Executive Chairman Thoren Daniel J. converted options into 5,543 shares and covered exercise/tax liability with 1,593 shares, increasing direct ownership by 1% to 360,939 units (SEC Form 4) (withholding tax)
- VP-Finance; CFO Thome Christopher J. converted options into 1,643 shares and covered exercise/tax liability with 608 shares, increasing direct ownership by 4% to 30,562 units (SEC Form 4) (tax liability)
- President and CEO Malone Matthew converted options into 1,291 shares and covered exercise/tax liability with 371 shares, increasing direct ownership by 2% to 57,487 units (SEC Form 4) (withholding obligation)
- SEC Form 10-K filed by Graham Corporation
- SEC Form 8-K filed by Graham Corporation
- Graham Corporation Reports Fourth Quarter and Full-Year Fiscal 2026 Results
- SEC Form 8-K filed by Graham Corporation
- Director Painter Jonathan W converted options into 1,956 shares, increasing direct ownership by 6% to 34,556 units (SEC Form 4)
- Director Stoner Troy A. converted options into 1,956 shares, increasing direct ownership by 12% to 18,623 units (SEC Form 4)
- Director Schnorr Lisa M. converted options into 1,956 shares, increasing direct ownership by 5% to 37,867 units (SEC Form 4)
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)